Related Experiment Video
Updated: Jul 20, 2025

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Type 2 diabetes susceptibility gene GRK5 regulates physiological pancreatic β-cell proliferation via phosphorylation
Shugo Sasaki1,2, Cuilan Nian1,2,3, Eric E Xu1,3
1BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Abstract:
Restoring functional β cell mass is a potential therapy for those with diabetes. However, the pathways regulating β cell mass are not fully understood. Previously, we demonstrated that Sox4 is required for β cell proliferation during prediabetes. Here, we report that Sox4 regulates β cell mass through modulating expression of the type 2 diabetes (T2D) susceptibility gene GRK5. β cell-specific Grk5 knockout mice showed impaired glucose tolerance with reduced β cell mass, which was accompanied by upregulation of cell cycle inhibitor gene Cdkn1a. Furthermore, we found that Grk5 may drive β cell proliferation through a pathway that includes phosphorylation of HDAC5 and subsequent transcription of immediate-early genes (IEGs) such as Nr4a1, Fosb, Junb, Arc, Egr1, and Srf. Together, these studies suggest GRK5 is linked to T2D through regulation of β cell growth and that it may be a target to preserve β cells during the development of T2D.
Insights
This study reveals that GRK5 is crucial for maintaining beta cell mass and function, impacting glucose tolerance. Targeting GRK5 may offer a new therapeutic strategy for type 2 diabetes (T2D) by preserving beta cells.
Area of Science:
- Endocrinology
- Molecular Biology
- Diabetes Research
Background:
- Restoring functional beta cell mass is a key therapeutic goal for diabetes.
- Understanding the pathways that regulate beta cell mass is essential for developing effective treatments.
- Previous work identified Sox4 as critical for beta cell proliferation in prediabetes.
Purpose of the Study:
- To investigate the role of Sox4 in regulating beta cell mass.
- To elucidate the connection between Sox4, GRK5, and beta cell mass.
- To explore GRK5 as a potential therapeutic target for type 2 diabetes (T2D).
Main Methods:
- Examined the effect of Sox4 on GRK5 expression in beta cells.
- Generated beta cell-specific Grk5 knockout mice.
- Assessed glucose tolerance and beta cell mass in knockout mice.
- Investigated the downstream signaling pathway of GRK5, including HDAC5 phosphorylation and immediate-early gene (IEG) expression.
Main Results:
- Sox4 regulates beta cell mass by modulating the expression of the T2D susceptibility gene GRK5.
- Beta cell-specific Grk5 knockout mice exhibited impaired glucose tolerance and reduced beta cell mass.
- Reduced beta cell mass in knockout mice was associated with increased expression of the cell cycle inhibitor gene Cdkn1a.
- GRK5 appears to promote beta cell proliferation via a pathway involving HDAC5 phosphorylation and subsequent transcription of IEGs like Nr4a1, Fosb, Junb, Arc, Egr1, and Srf.
Conclusions:
- GRK5 plays a significant role in regulating beta cell growth and is linked to T2D pathogenesis.
- GRK5 may serve as a therapeutic target for preserving beta cell function and mass during T2D development.
Related Concept Videos
Cell Specific Gene Expression
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
PI3K/mTOR/AKT Signaling Pathway
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes Mellitus: Type 2 and Gestational

